Prostate Cancer

On today’s Health Living Segment with Baptist Health Dr. Basham. Will explain how robots are being used to treat prostate cancer.  In the United States, the most common way prostate cancer is treated is robotic prostatectomy. The advantages of the robotic platform over standard microscopic surgery are about 3 fold. The surgeon gets a three-dimensional view inside the body with a great deal of magnification to see the tissue with precise detail to be able to operate on it with great efficiency. Besides that, the robot itself mimics the surgeon’s movement with very close accuracy. It eliminates any trimmer and it’s a very reliable platform. The current guidelines are the most men around the age 55 start to talk to their doctor about getting screened which is a combination of either a blood test called a PSA or a digital rectal exam to take a feel of the prostate. For more information on men’s health visit Baptist-Health.com Please enable Javascript to watch this video Sponsored

The Prostate Cancer Foundation Scholar-in-Training Awards recognize promising young cancer researchers presenting outstanding proffered papers relating to advanced prostate cancer at the American Association for Cancer Research (AACR) Annual Meeting. The Prostate Cancer Foundation is one of 17 organizations sponsoring this highly competitive awards program in conjunction with the AACR. The 2019 AACR Annual Meeting will be held from March 29 to April 3 at the Georgia World Congress Center in Atlanta, Georgia. Andi K. Cani, MS University of Michigan, Ann Arbor, MI Email: acani@med.umich.edu Abstract #914 Development of a whole-urine, next-generation sequencing-based assay for early detection of aggressive prostate cancer Andi K. Cani, Kevin Hu, Javed Siddiqui, Sumin Han, Daniel H. Hovelson, Chia-Jen Liu, Simpa S. Salami, Ganesh S. Palapattu, Todd M. Morgan, John T. Wei, Arul M. Chinnaiyan, Scott A. Tomlins. University of Michigan, Ann Arbor, MI Despite advances in biomarker devel

THURSDAY, March 28, 2019 (HealthDay News) — Adding docetaxel-based chemotherapy (CT) to standard treatment for high-risk nonmetastatic prostate cancer improves survival, according to a study published online March 12 in the Journal of Clinical Oncology . Seth A. Rosenthal, M.D., from Sutter Cancer Centers in Sacramento, California, and colleagues assessed whether docetaxel CT could improve overall survival and clinical outcomes among patients with high-risk nonmetastatic prostate cancer. A total of 563 patients were randomly assigned to receive standard long-term androgen suppression (AS) plus radiotherapy (RT) with or without adjuvant CT. The researchers found that during a median follow-up of 5.7 years, the four-year overall survival rate was 89 percent for AS + RT and 93 percent for AS + RT + CT (hazard ratio [HR], 0.69). There were fewer deaths resulting from prostate cancer in the AS + RT + CT arm versus AS + RT (23 versus 16 deaths). The six-year rate of distant metastasis was

Prostate cancer researchers dedicate their lives working in labs and clinics, collaborating with colleagues, designing experiments and trials… all with one big goal in mind: to help patients. Whether it’s exploring the biology of cancer in the lab or conducting clinical trials with patients, research eventually converges into better treatments. But how are these discoveries communicated to practicing doctors? The urologist who takes your blood for your PSA usually has little to do with the doctor who developed the test. One way that information is spread is through major scientific conferences : several times a year, researchers, clinicians, science writers, experts from the pharmaceutical industry, patient advocates, and, of course, leaders from PCF gather under one roof for a few information-packed days to present and discuss the most important developments in the prostate cancer field. Everyone comes away inspired – a researcher plans to try a new approach to a vexing challeng

Although recent advances in the treatment of castration-resistant prostate cancer (CRPC) have significantly improved patient outcomes, advanced prostate cancer is still associated with substantial morbidity and mortality, particularly in patients who develop resistance after multiple lines of therapy. Various cell signaling, DNA repair, and epigenetic enzymatic pathways are being targeted with small-molecule inhibitors in order to identify treatment strategies for patients with CRPC. In this review, we discuss novel targets and agents, studied preclinically and now being validated in clinical trials, including poly ADP-ribose polymerase (PARP), enhancer of zeste homologue 2 (EZH2), hedgehog pathway, MDM2/p53, and tyrosine kinase inhibitors. Further, we outline current approaches for novel prostate cancer vaccines such as DCVAC/PCa, PROSTVAC-V/F, MVI-816, CV9104, and PF-06753512. This wide spectrum of potential treatment strategies holds promise for additional improvements in the treatm

Current National Comprehensive Cancer Network guidelines and Gleason scores proved unreliable in stratifying men with prostate cancer based on the presence or absence of pathogenic germline variants, according to study results published in JAMA Oncology. Simplifying and expanding testing guidelines for genetic mutations would improve management of these men, according to the researchers. “Guidelines specifically addressing genetic testing for patients with prostate cancer were sparse until recently,” Piper Nicolosi, PhD, researcher in clinical genomics at Invitae Corp. in San Francisco, and colleagues wrote. “The purpose of this study was to evaluate the prevalence of germline mutations in a large, diverse cohort with prostate cancer with respect to current genetic testing guidelines and to bridge gaps in knowledge given the heterogeneity in both prostate cancer and germline testing recommendations.” In the cross-sectional study, Nicolosi and colleagues reviewed data from 3,607 m

By Marilynn Larkin NEW YORK (Reuters Health) - Gallium-68 prostate-specific membrane antigen positron emission tomography (Ga-68 PSMA PET) accurately detects metastases in biochemically recurrent prostate cancer, particularly at low prostate-specific antigen (PSA) levels, researchers say. "Historically, conventional imaging modalities have included computerized tomography and whole body radionucleotide bone scans," Dr. Marlon Perera of the University of Melbourne in Victoria, Australia told Reuters Health by email. "While cost-effective and readily available, these conventional imaging modalities are fraught with limited accuracy." "Ga-68 PSMA PET is a novel imaging technique," he said. "PSMA is a transmembrane ligand that is expressed on prostatic cells. Excitingly, the expression of PSMA increases with increasing cellular dysplasia (i.e., more malignant). Accordingly, this represents an ideal target for imaging in prostate cancer." In a 201

diseases around zirka30 percent of all malignant cancers in men are prostate cancers. Thus, prostate cancer in men the most frequently diagnosed malignant Tumor. Year 6 affected about 100 men. Around 1’400 men die each year as a result of a disease. Since there are very aggressive forms, the early detection has a significant influence on the prognosis – however, it is not without controversy. The prostate gland or pilot heard the gland to the internal genital organs of the man. She is a chestnut large, is below the bladder and surrounds part of the urethra. There, it has various functions; they produced, for example, a Secretion that mixes with the sperm, and about 30 percent of ejaculate. What are the risks for prostate cancer are there? as soon As prostate cells mutate and multiply, forming a Tumor. The prostate gland is divided into an Outer and an inner zone as well as in a so – called mantle zone; the most common tumors to form in the outer zone, which lies close to the rectum

Article Tools Q: How does prostate cancer happen? And what are the symptoms? I’m only 43, but I worry that I wouldn’t recognize the signs if I had it. A: Prostate cancer is one of the most common cancers among men in the United States. It occurs in the prostate gland, a male reproductive organ that sits between the penis and the rectum, just beneath the bladder. The prostate, which is about the size of a golf ball, wraps around the urethra, which is the duct through which urine and semen exit the body. When normal cell division goes awry, the chaotic and uncontrolled growth that results is what we know as cancer. In prostate cancer, the rogue cells use hormones known as androgens, which include testosterone, to fuel their growth. Although prostate cancers begin within the gland, they can spread to nearby regions of the body, including the lymph nodes. Some prostate cancers are slow to grow and can take years to be detected. When slow-growing cancers are identified, the risk they p

Prostate cancer researchers dedicate their lives working in labs and clinics, collaborating with colleagues, designing experiments and trials… all with one big goal in mind: to help patients. Whether it’s exploring the biology of cancer in the lab or conducting clinical trials with patients, research eventually converges into better treatments. But how are these discoveries communicated to practicing doctors? The urologist who takes your blood for your PSA usually has little to do with the doctor who developed the test. One way that information is spread is through major scientific conferences : several times a year, researchers, clinicians, science writers, experts from the pharmaceutical industry, patient advocates, and, of course, leaders from PCF gather under one roof for a few information-packed days to present and discuss the most important developments in the prostate cancer field. Everyone comes away inspired – a researcher plans to try a new approach to a vexing challeng

270   0 Posted on Mar 28, 2019, 9 p.m. For men getting up in their years fear of prostate cancer can be of great concern, with it being the second most common form of cancer among men within the USA, having over 160,000 new diagnosis every year, as published in the journal The Lancet. If diagnosed early the prognosis for men affected by this form of cancer is good, however this disease still claims over 26,000 lives every year, making fears over it hold weight. University College London has recently conducted some research which may offer hope for those with prostate cancer. The phase III clinical trial involved 413 patients which were treated at 47 different centers in 10 European countries, funded by STEBA Biotech whom holds the patent for vascular targeted photodynamic therapy. VTP therapy involves injecting light sensitive drug WST11 directly into the patient bloodstream, then activating the drug via a laser causing the tumor tissue to die. WST11 is cultivated from bacteria

Racial differences have long been evident in prostate cancer statistics. In particular, African American men are diagnosed with prostate cancer more often than white men, and they’re also nearly twice as likely to die of the disease. But new research also shows that African American men who receive the most advanced treatments for late-stage prostate cancer can live at least as long — or even longer — than their Caucasian counterparts. Why is this the case? Scientists are searching for an explanation. “The fact that African American men have better survival is of huge research interest,” said Dr. Stephen Freedland, a urologist at Cedars-Sinai Medical Center in Los Angeles. “If we can figure this out, we’ll obtain key insights into the factors driving survival in late-stage prostate cancer. And that in turn will help spur better treatments for all men — regardless of race.” Each year, about 160 per 100,000 African American men receive a prostate cancer diagnosis. That’s three times

The five-year survival rate of prostate cancer at Shanghai Cancer Center has reached 82.6 percent, much higher than the national average of 69.2 percent. The rise of five-year survival, recovery in clinical term, is due to the adoption of multidisciplinary diagnosis and treatment, screening for early-stage detection and improved medical skills, said Dr Ye Dingwei, vice president of Shanghai Cancer Center, the leading cancer hospital in the country. The hospital conducted over 1,000 prostate cancer surgeries last year. To improve patient management and diagnosis and treatment, the hospital has set up the nation’s first prostate cancer patient management database and online platform for long-distance consultation and discussion. “We are pushing early screening for high risk groups,” Ye said. “The five-year survival rate is over 90 percent in the United States because of the wide adoption of early screening. About 95 percent of patients there in early stage, but only 50 to 60 percent

78   0 Posted on Mar 28, 2019, 9 p.m. For men getting up in their years fear of prostate cancer can be of great concern, with it being the second most common form of cancer among men within the USA, having over 160,000 new diagnosis every year, as published in the journal The Lancet. If diagnosed early the prognosis for men affected by this form of cancer is good, however this disease still claims over 26,000 lives every year, making fears over it hold weight. University College London has recently conducted some research which may offer hope for those with prostate cancer. The phase III clinical trial involved 413 patients which were treated at 47 different centers in 10 European countries, funded by STEBA Biotech whom holds the patent for vascular targeted photodynamic therapy. VTP therapy involves injecting light sensitive drug WST11 directly into the patient bloodstream, then activating the drug via a laser causing the tumor tissue to die. WST11 is cultivated from bacteria t

45   0 Posted on Mar 28, 2019, 9 p.m. For men getting up in their years fear of prostate cancer can be of great concern, with it being the second most common form of cancer among men within the USA, having over 160,000 new diagnosis every year, as published in the journal The Lancet. If diagnosed early the prognosis for men affected by this form of cancer is good, however this disease still claims over 26,000 lives every year, making fears over it hold weight. University College London has recently conducted some research which may offer hope for those with prostate cancer. The phase III clinical trial involved 413 patients which were treated at 47 different centers in 10 European countries, funded by STEBA Biotech whom holds the patent for vascular targeted photodynamic therapy. VTP therapy involves injecting light sensitive drug WST11 directly into the patient bloodstream, then activating the drug via a laser causing the tumor tissue to die. WST11 is cultivated from bacteria t

NEW YORK (GenomeWeb) – After presenting initial validation data on a prostate cancer microRNA-based urine assay that is designed to aid diagnosis, provide prognosis, and monitor disease progression, MiR Scientific believes it is prepared to launch tests for both bladder and prostate cancer by the end of this year or early next. Get the full story with GenomeWeb Premium Only $95 for the first 90 days* GenomeWeb Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives Never miss another important industry story. Try GenomeWeb Premium now. You may already have institutional access! Check if I qualify. Already a GenomeWeb or 360Dx Premium member? Login Now . * Before your trial expires, we’ll put together a custom quote with your long-term premium options. https://ift.tt/2YstjPj

Q: How does prostate cancer happen? And what are the symptoms? I'm only 43, but I worry that I wouldn't recognize the signs if I had it. A: Prostate cancer is one of the most common cancers among men in the United States. It occurs in the prostate gland, a male reproductive organ that sits between the penis and the rectum, just beneath the bladder. The prostate, which is about the size of a golf ball, wraps around the urethra, which is the duct through which urine and semen exit the body. One of the roles of the prostate is to produce fluids that nurture and support sperm, and to propel these fluids into the urethra when needed. When normal cell division goes awry, the chaotic and uncontrolled growth that results is what we know as cancer. In prostate cancer, the rogue cells use hormones known as androgens, which include testosterone, to fuel their growth. Although prostate cancers begin within the gland, they can spread to nearby regions of the body, including the lymph node

Dear Doctor: How does prostate cancer happen? And what are the symptoms? I’m only 43, but I worry that I wouldn’t recognize the signs if I had it. Dear Reader: Prostate cancer is one of the most common cancers among men in the United States. It occurs in the prostate gland, a male reproductive organ that sits between the penis and the rectum, just beneath the bladder. The prostate, which is about the size of a golf ball, wraps around the urethra, which is the duct through which urine and semen exit the body. One of the roles of the prostate is to produce fluids that nurture and support sperm, and to propel these fluids into the urethra when needed. When normal cell division goes awry, the chaotic and uncontrolled growth that results is what we know as cancer. In prostate cancer, the rogue cells use hormones known as androgens, which include testosterone, to fuel their growth. Although prostate cancers begin within the gland, they can spread to nearby regions of the body, includ

Radium-223 has improved overall survival (OS) and reduced symptomatic skeletal events (SSE) in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases (ALSYMPCA trial). Our aim was to assess clinical and biochemical factors related to survival, safety and survival outcomes of Radium-223 in a clinical practice setting. We retrospectively analysed 32 mCRPC patients treated with Radium-223, assessing bone scan, pain reduction, alkaline phosphatase (ALP) and prostate-specific antigen (PSA) response (≥30% reduction). At scintigraphic assessment, 41% had partial response with a disease control rate of 91%; 56% had ALP response and 25% had PSA response; 41% had pain reduction with pain control of 72%. Scintigraphic response and stability were correlated with longer median progression-free survival (mPFS) (13 and 12 vs. 6 months; P=0.002) and mOS (16 and 12 vs. 6 months; P=0.003). ALP response was associated with longer mPFS (13 vs. 12 months; P=0.2) and mOS (

Prostate MRI is increasingly being used in men with a clinical suspicion of prostate cancer (PCa). However, development and validation of methods for focal therapy planning are still lagging. To evaluate the diagnostic accuracy on lesion, region-of-interest (ROI), and voxel level of IMPROD biparametric prostate MRI (bpMRI) for PCa detection in men with a clinical suspicion of PCa who subsequently underwent radical prostatectomy. Prospective single-institution clinical trial (NCT01864135). Sixty-four men who underwent radical prostatectomy after IMPROD bpMRI performed in prebiopsy settings. IMPROD bpMRI consisted of T2 -weighted imaging (T2 w) and three separate diffusion-weighted imaging acquisitions with an average acquisition time of 15 minutes. The diagnostic accuracy of prospectively reported manual cancer delineations and regions increased with 3D dilation were evaluated on the voxel level (volume of 1.17 mm3 , 1 mm3 , 125 mm3 ) as well as the 36 ROI level. Only PCa lesions w

Q: How does prostate cancer happen? And what are the symptoms? I'm only 43, but I worry that I wouldn't recognize the signs if I had it. A: Prostate cancer is one of the most common cancers among men in the United States. It occurs in the prostate gland, a male reproductive organ that sits between the penis and the rectum, just beneath the bladder. The prostate, which is about the size of a golf ball, wraps around the urethra, which is the duct through which urine and semen exit the body. One of the roles of the prostate is to produce fluids that nurture and support sperm, and to propel these fluids into the urethra when needed. When normal cell division goes awry, the chaotic and uncontrolled growth that results is what we know as cancer. In prostate cancer, the rogue cells use hormones known as androgens, which include testosterone, to fuel their growth. Although prostate cancers begin within the gland, they can spread to nearby regions of the body, including the lymph node

Dear Doctor: How does prostate cancer happen? And what are the symptoms? I'm only 43, but I worry that I wouldn't recognize the signs if I had it. Dear Reader: Prostate cancer is one of the most common cancers among men in the United States. It occurs in the prostate gland, a male reproductive organ that sits between the penis and the rectum, just beneath the bladder. The prostate, which is about the size of a golf ball, wraps around the urethra, which is the duct through which urine and semen exit the body. One of the roles of the prostate is to produce fluids that nurture and support sperm, and to propel these fluids into the urethra when needed. When normal cell division goes awry, the chaotic and uncontrolled growth that results is what we know as cancer. In prostate cancer, the rogue cells use hormones known as androgens, which include testosterone, to fuel their growth. Although prostate cancers begin within the gland, they can spread to nearby regions of the body, i

Bilharzia, also known as ‘snail fever’ or schistosomiasis, is an infection caused by microscopic parasitic worms. The parasites are rife in areas of freshwater, such as rivers and lakes, in popular holiday destinations including Kenya, Tanzania, Lake Malawi, South Africa, Egypt and Brazil. They penetrate the skin of people who have swum or come into contact with contaminated water. This could also include taking a shower with unfiltered water that comes directly from lakes or rivers. According to new research by the University of Ghana, being struck down with bilharzia also puts victims at an increased risk of developing prostate cancer . The team of researchers analysed urine samples from patients with bilharzia and examined their prostate cells. They found the disease induced “oxidative stress” in the prostate cells, which in turn caused cellular abnormalities, ultimately “promoting” prostate cancer. “This study, for the first time, has provided empirical evidence on the poss

genprowebdirectory Scroll Up MORE CONTENT We use cookies to give you a better experience on genengnews.com. By continuing to use our site, you are agreeing to the use of cookies as set in our privacy policy. Got it! https://ift.tt/2Or8fnA

365   0 Posted on Mar 26, 2019, 6 p.m. How prostate cancer cells release a protein that is taken up by surrounding normal and cancer cells has been demonstrated which may promote tumour growth and help to protect cancer from the immune system, as published in Scientific Reports. “In order for tumors to survive, grow bigger, and spread they have to control behavior of cancer cells and normal cells around them, we have found a means by which they do this; blocking the process may be a potential target for future cancer therapy.” explains Professor Richard Morgan, PhD. “Protein transcription factor engrailed-2 is a nuclear protein that plays roles in early brain development which is also found at high levels in a variety of different cancer types.” “... early studies indicated EN2 has oncogenic function in breast cancer cells as its forced expression in non-tumorigenic mammary cell lines resulted in a number of malignant characteristics… more recently has been shown to be expressed

Prostate cancer researchers dedicate their lives working in labs and clinics, collaborating with colleagues, designing experiments and trials… all with one big goal in mind: to help patients. Whether it’s exploring the biology of cancer in the lab or conducting clinical trials with patients, research eventually converges into better treatments. But how are these discoveries communicated to practicing doctors? The urologist who takes your blood for your PSA usually has little to do with the doctor who developed the test. One way that information is spread is through major scientific conferences : several times a year, researchers, clinicians, science writers, experts from the pharmaceutical industry, patient advocates, and, of course, leaders from PCF gather under one roof for a few information-packed days to present and discuss the most important developments in the prostate cancer field. Everyone comes away inspired – a researcher plans to try a new approach to a vexing challeng